# US 2024/0200097 A1 · Aav capsids with increased tropism to brain tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200097 A1
- Document ID: US20240200097A1
- Status: Published application
- Kind: A1
- Application number: 18/511,290
- Filed: 2023-11-16
- Published: 2024-06-20
- Earliest claimed: 2020-05-13
- Assignees: Voyager Therapeutics, Inc.
- Applicants: Voyager Therapeutics, Inc.
- Inventors: Mathieu E. Nonnenmacher; Jinzhao Hou; Wei Wang; Matthew Child; Shaoyong Li
- Web page: https://patentgrep.com/patent/US20240200097A1

## CPC

- C12N 15/86: Viral vectors
- A61K 35/761: Adenovirus
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

The disclosure relates to compositions, methods, and processes for the preparation, use, and/or formulation of adeno-associated virus capsid proteins, wherein the capsid proteins comprise targeting peptide inserts for enhanced tropism to a target tissue.

## Claims

### Claim at position 1

-51. (canceled)

### Claim 52

An AAV capsid variant, comprising:
(a) the amino acid sequence of any of SEQ ID NOs: 3648-3659 or 1725-3622;
(b) an amino acid sequence comprising at least 5, 6, 7, 8, or 9 consecutive amino acids from the amino acid sequence of any of SEQ ID NO: 3648-3659 or 1725-3622; or
(c) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions, relative to the amino acid sequence of any of 3648-3659 or 1725-3622;
wherein the capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 95% sequence identity thereto, and
wherein the amino acid sequence of (a), (b), or (c) is present immediately subsequent to position 586, 588, or 589, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

### Claim 53 (depends on 52)

The AAV capsid variant of claim 52, which comprises
(a) the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648), or at least 5, 6, 7, or 8 consecutive amino acids from the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648);
(b) the amino acid sequence of IVMNSLK (SEQ ID NO: 3651), or at least 4, 5, or 6 consecutive amino acids from the amino acid sequence of IVMNSLK (SEQ ID NO: 3651); or
(c) the amino acid sequence of YSTDVRM (SEQ ID NO: 3650), YSTDERM (SEQ ID NO: 3657), or YSTDERK (SEQ ID NO: 3658), or at least 4, 5, or 6 consecutive amino acids from the amino acid sequence of YSTDVRM (SEQ ID NO: 3650), YSTDERM (SEQ ID NO: 3657), or YSTDERK (SEQ ID NO: 3658).

### Claim 54 (depends on 52)

The AAV capsid variant of claim 52, comprising:
(i) the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648), wherein the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648) is present immediately subsequent to position 586, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138;
(ii) the amino acid sequence of GGTLAVVSL (SEQ ID NO: 3654), wherein the amino acid sequence of GGTLAVVSL (SEQ ID NO: 3654) is present immediately subsequent to position 586, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138;
(iii) the amino acid sequence of IVMNSLK (SEQ ID NO: 3651), wherein the amino acid sequence of IVMNSLK (SEQ ID NO: 3651) is present immediately subsequent to position 588, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138; or
(iv) the amino acid sequence of any of SEQ ID NOs: 3649, 3650, 3652, 3653, or 3655-3659, wherein the amino acid sequence of any of the aforesaid sequences is present immediately subsequent to position 589, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

### Claim 55 (depends on 52)

The AAV capsid variant of claim 52, wherein:
(i) the AAV capsid variant further comprises a substitution at position K449, numbered according to SEQ ID NO: 138;
(ii) the AAV capsid variant further comprises an insertion, substitution, and/or deletion, in loop I, II, IV and/or VI;
(iii) the AAV capsid variant comprises an amino acid residue other than “A” at position 587 and/or an amino acid residue other than “Q” at position 588, numbered according to SEQ ID NO: 138; or
(iv) the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 137, or a sequence with at least 95% sequence identity thereto.

### Claim 56 (depends on 52)

The AAV capsid variant claim 52, wherein:
(i) the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 3636-3647, or an amino acid sequence with at least 95% sequence identity thereto; or
(ii) the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of any one of SEQ ID NOs: 3623-3635, or a nucleotide sequence with at least 90% sequence identity thereto.

### Claim 57 (depends on 52)

The AAV capsid variant of claim 52, wherein the AAV capsid variant:
(i) is enriched at least about 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 100, 200, 300, or 400-fold, in the brain compared to a reference sequence of SEQ ID NO: 138;
(ii) transduces a brain region, e.g., selected from dentate nucleus, cerebellar cortex, cerebral cortex, brain stem, hippocampus, thalamus and putamen, wherein the level of transduction is at least 5, 10, 50, 100, 200, 500, 1,000, 2,000, 5,000, or 10,000-fold greater as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from an immunohistochemistry assay, a qRT-PCR, or a RT-ddPCR assay;
(iii) delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 500, 1,000, 2,000, 5,000, or 10,000-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from a qRT-PCR or a RT-ddPCR assay, wherein the brain region comprises a frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, hippocampus, or a combination thereof;
(iv) delivers an increased level of a payload to a spinal cord region, optionally wherein the level of the payload is increased by at least 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800 or 900-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from a qRT-PCR assay, wherein the spinal cord region comprises a cervical, thoracic, lumbar region, or a combination thereof; and/or
(v) delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 5, 10, 20, 30, 40 or 50-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from a qRT-PCR or a RT-ddPCR assay, wherein the brain region comprises a frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, hippocampus, or a combination thereof.

### Claim 58

An AAV capsid variant, comprising:
(i) the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648);
(ii) an amino acid sequence comprising at least 5, 6, 7, 8, or 9 consecutive amino acids from the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648); or
(iii) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions, relative to the amino acid sequence of PLNGAVHLY (SEQ ID NO: 3648); and
wherein the capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 95% sequence identity thereto.

### Claim 59 (depends on 58)

The AAV capsid variant of claim 58, wherein the amino acid sequence of (i), (ii), or (iii):
(a) is present in loop VIII, relative to a reference sequence of SEQ ID NO: 138; or
(b) is present immediately subsequent to position 586, relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138.

### Claim 60 (depends on 58)

The AAV capsid variant of claim 58, wherein the AAV capsid variant:
(i) is enriched at least about 300 or 400-fold in the brain compared to a reference sequence of SEQ ID NO: 138;
(ii) transduces a brain region selected from dentate nucleus, cerebellar cortex, cerebral cortex, brain stem, hippocampus, thalamus and putamen, wherein the level of transduction is at least 500, 1,000, 2,000, 5,000, or 10,000-fold greater as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from an immunohistochemistry assay, a qRT-PCR, or a RT-ddPCR assay;
(iii) delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 500, 1,000, 2,000, 5,000, or 10,000-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay, chosen from a qRT-PCR or a RT-ddPCR assay, wherein the brain region comprises a frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, hippocampus, or a combination thereof;
(iv) delivers an increased level of a payload to a spinal cord region, optionally wherein the level of the payload is increased by at least 50, 100, 200, 300, 400, 500, 600, 700, 800 or 900-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay, chosen from a qRT-PCR assay, wherein the spinal cord region comprises a cervical, thoracic, lumbar region, or a combination thereof; and/or
(v) delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 5, 10, 20, 30, 40 or 50-fold, as compared to a reference sequence of SEQ ID NO: 138, when measured by an assay chosen from a qRT-PCR or a RT-ddPCR assay, wherein the brain region comprises a frontal cortex, sensory cortex, motor cortex, putamen, thalamus, cerebellar cortex, dentate nucleus, caudate, hippocampus, or combination thereof.

### Claim 61

An AAV capsid variant, comprising:
(i) the amino acid sequence of IVMNSLK (SEQ ID NO: 3651);
(ii) an amino acid sequence comprising at least 5, 6, or 7 consecutive amino acids from the amino acid sequence of IVMNSLK (SEQ ID NO: 3651); or
(iii) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions, relative to the amino acid sequence of IVMNSLK (SEQ ID NO: 3651); and
wherein the capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 95% sequence identity thereto.

### Claim 62 (depends on 61)

The AAV capsid variant of claim 61, wherein the AAV capsid variant:
(i) has an increased tropism for a muscle cell or tissue, e.g., a heart tissue, relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138; and/or
(ii) delivers an increased level of a payload to a muscle region, optionally wherein the level of the payload is increased by at least 10, 15, 20, 30, or 40-fold, as compared to a reference sequence of SEQ ID NO: 138 when measured by an assay chosen from an IHC assay or a RT-ddPCR assay, optionally wherein the muscle region comprises a heart muscle (e.g., a heart atrium muscle region or a heart ventricle muscle region), quadriceps muscle, a diaphragm muscle region, or a combination thereof.

### Claim 63 (depends on 52)

A polynucleotide encoding the AAV capsid variant of claim 52, or which comprises the nucleotide sequence of any one of SEQ ID NOs: 3623-3635, or a nucleotide sequence with at least 90% sequence identity thereto.

### Claim 64 (depends on 52)

An AAV particle comprising the AAV capsid variant of claim 52.

### Claim 65 (depends on 64)

The AAV particle of claim 64, which comprises a nucleotide sequence encoding a payload comprising a therapeutic protein or functional variant thereof; an antibody or antibody fragment; an enzyme; a component of a gene editing system; an RNAi agent; or a combination thereof.

### Claim 66 (depends on 65)

The AAV particle of claim 65, wherein the therapeutic protein or functional variant thereof is:
(i) associated with a neurological or neurodegenerative disorder, a muscular or neuromuscular disorder, or a neuro-oncological disorder; or
(ii) chosen from apolipoprotein E (APOE); human survival of motor neuron (SMN) 1 or SMN2; glucocerebrosidase (GBA1); aromatic L-amino acid decarboxylase (AADC); aspartoacylase (ASPA); tripeptidyl peptidase I (CLN2); beta-galactosidase (GLB1); N-sulphoglucosamine sulphohydrolase (SGSH); N-acetyl-alpha-glucosaminidase (NAGLU); iduronate 2-sulfatase (IDS);
intracellular cholesterol transporter (NPC1); gigaxonin (GAN); or a combination thereof.

### Claim 67 (depends on 65)

The AAV particle of claim 65, wherein the antibody or antibody binding fragment binds to:
(a) an antigen associated with a neurological or neurodegenerative disorder chosen from 3-amyloid, APOE, tau, SOD1, TDP-43, huntingtin (HTT), synuclein, or a combination thereof;
(b) an antigen associated with a muscular or neuromuscular disorder; or
(c) an antigen associated with a neuro-oncological disorder, chosen from HER2, EGFR, EGFRvIII, or a combination thereof.

### Claim 68 (depends on 65)

The AAV particle of claim 65, wherein:
(iii) the enzyme comprises a meganuclease, a zinc finger nuclease, a TALEN, a recombinase, integrase, a base editor, a Cas9, or a fragment thereof;
(iv) the component of a gene editing system comprises one or more components of a CRISPR-Cas system; or
(v) the RNAi agent inhibits expression of a CNS related gene chosen from SOD1, MAPT, APOE, HTT, C90RF72, TDP-43, APP, BACE, SNCA, ATXN1, ATXN3, ATXN7, SCN1A-SCN5A, SCN8A-SCN11A, or a combination thereof.

### Claim 69 (depends on 64)

The AAV particle of claim 64, which comprises a viral genome comprising a promoter operably linked to the nucleic acid sequence encoding the payload, wherein, the promoter is chosen from human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate-early enhancer and/or promoter, chicken β-actin (CBA) and its derivative CAG, β glucuronidase (GUSB), or ubiquitin C (UBC), neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B-chain (PDGF-β), intercellular adhesion molecule 2 (ICAM-2), synapsin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca2+/calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light (NFL) or heavy (NFH), β-globin minigene nβ2, preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2), glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), a cardiovascular promoter, a liver promoter, a skeletal muscle promoter, or a fragment or a functional variant thereof.

### Claim 70 (depends on 69)

The AAV particle of claim 69, wherein the viral genome further comprises:
(i) a polyA signal sequence;
(ii) an inverted terminal repeat (ITR) sequence, wherein the ITR sequence is positioned 5′ relative to the encoded payload and/or the ITR sequence is positioned 3′ relative to the encoded payload;
(iii) an enhancer, a Kozak sequence, an intron region, and/or an exon region;
(iv) a miR binding site that reduces expression of the payload encoded by the viral genome in a cell or tissue where the corresponding miRNA is expressed; and/or
(v) a nucleotide sequence encoding a Rep protein, wherein the Rep protein comprises a Rep78 protein, a Rep68, Rep52 protein, a Rep40 protein or a combination thereof.

### Claim 71 (depends on 70)

The AAV particle of claim 70, wherein the viral genome comprises:
(i) at least 1-5 copies of the miR binding site;
(ii) at least 3 copies of the miR binding site, wherein all three copies comprise the same miR binding site, or at least one, two, or all of the copies comprise a different miR binding site; and/or
(iii) at least 4 copies of the miR binding site, wherein all four copies comprise the same miR binding site, or at least one, two, three, or all of the copies comprise a different miR binding site.

### Claim 72 (depends on 70)

The AAV particle of claim 70, wherein the miR binding site comprises at least 1-5 copies of a miR122 binding site, a miR183 binding site, a miR-142-3p, or a combination thereof, wherein:
(i) the miR122 binding site comprises the nucleotide sequence of SEQ ID NO: 3672, or a nucleotide sequence having at least 85% sequence identity thereto; or a nucleotide sequence having at least one, two, three, or four modifications, but no more than ten modifications relative to SEQ ID NO: 3672;
(ii) the miR183 binding site comprises the nucleotide sequence of SEQ ID NO: 3675, or a nucleotide sequence having at least 85% sequence identity thereto; or a nucleotide sequence having at least one, two, three, or four modifications, but no more than ten modifications relative to SEQ ID NO: 3675; and/or
(iii) the miR-142-3p binding site comprises the nucleotide sequence of SEQ ID NO: 3674, or a nucleotide sequence having at least 85% sequence identity thereto; or a nucleotide sequence having at least one, two, three, or four modifications, but no more than ten modifications relative to SEQ ID NO: 3674.

### Claim 73 (depends on 52)

A vector comprising a polynucleotide encoding the AAV capsid variant of claim 52.

### Claim 74 (depends on 52)

A cell comprising the AAV capsid variant of claim 52, wherein:
(i) the cell is a mammalian cell or an insect cell;
(ii) the cell is a cell of a brain region or a spinal cord region, chosen from a cell of the frontal cortex, sensory cortex, motor cortex, caudate, dentate nucleus, cerebellar cortex, cerebral cortex, brain stem, hippocampus, thalamus, putamen, cervical spinal cord region, thoracic spinal cord region, lumbar spinal cord region, or a combination thereof;
(iii) a neuron, a sensory neuron, a motor neuron, or an astrocyte;
(iv) a muscle cell chosen from a cell of the heart, diaphragm, or quadriceps; or
(v) a cell of the heart atrium muscle or a heart ventricle muscle.

### Claim 75 (depends on 52)

A method of making an AAV particle, comprising
(i) providing a host cell comprising a viral genome; and
(ii) incubating the host cell under conditions suitable to enclose the viral genome in the AAV capsid variant of claim 52;
thereby making the AAV particle.

### Claim 76 (depends on 64)

A pharmaceutical composition comprising the AAV particle of claim 64, and a pharmaceutically acceptable excipient.

### Claim 77

A method of delivering a payload to a cell or tissue, comprising administering an effective amount of an AAV particle comprising an AAV capsid variant and a payload, wherein the AAV capsid variant comprises:
(a) the amino acid sequence of any of SEQ ID NO: 3648-3659 or 1725-3622;
(b) an amino acid sequence comprising at least 5, 6, 7, 8, or 9 consecutive amino acids from the amino acid sequence of any of SEQ ID NO: 3648-3659 or 1725-3622; or
(c) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions relative to the amino acid sequence of any of 3648-3659 or 1725-3622; and
wherein the capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 95% sequence identity thereto.

### Claim 78 (depends on 77)

The method of claim 77, wherein:
(i) the cell or tissue is a cell or tissue of a brain region or a spinal cord region chosen from a cell or tissue of the frontal cortex, sensory cortex, motor cortex, caudate, dentate nucleus, cerebellar cortex, cerebral cortex, brain stem, hippocampus, thalamus, putamen, cervical spinal cord region, thoracic spinal cord region, lumbar spinal cord region, or a combination thereof;
(ii) the cell is a neuron, a sensory neuron, a motor neuron, an astrocyte;
(iii) the cell is a muscle cell chosen from a cell of the heart, diaphragm, or quadriceps;
(iv) the cell or tissue is a heart muscle cell or tissue from the heart atrium or a heart ventricle; or
(v) the cell or tissue is within a subject, wherein the subject has, has been diagnosed with having, or is at risk of having a neurological disorder, a neurodegenerative disorder, a muscular disorder, a neuromuscular disorder, or a neuro-oncological disorder.

### Claim 79 (depends on 52)

A method of treating a subject having or diagnosed with having a neurological disorder, a neurodegenerative disorder, a muscular disorder, a neuromuscular disorder, or a neuro-oncological disorder comprising administering to the subject an effective amount of an AAV particle comprising the AAV capsid variant of claim 52 and a payload.

### Claim 80 (depends on 79)

The method of claim 79, wherein the AAV particle is administered to the subject:
(i) intravenously;
(ii) intramuscularly, intracerebrally, intrathecally, intracerebroventricularly, via intraparenchymal administration, or via intra-cisterna magna injection (ICM); or
(iii) via focused ultrasound (FUS), or via MRI-guided FUS coupled with intravenous administration.

### Claim 81 (depends on 79)

The method of claim 79, wherein the neurological disorder, neurodegenerative disorder, muscular disorder, neuromuscular disorder, or neuro-oncological disorder is Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS), Gaucher Disease, Dementia with Lewy Bodies, Parkinson's disease, Spinal Muscular Atrophy, Alzheimer's Disease, or cancer.
